Introduction
Prostate cancer is one of the most commonly diagnosed male cancers in the UK [1] , with incidence and survival rates varying between and within the UK's four constituent countries (England, Scotland, Wales, and Northern Ireland [NI]) [1] [2] [3] . In particular, higher incidence and better survival are typically found in more affluent areas [1, 4] , possibly reflecting levels of active case finding through prostate-specific antigen (PSA) testing [5] .
Treatment of prostate cancer also varies by NHS Hospital Trust within England [6] and between the four UK countries. Given that health-related quality of life [7] and urinary, bowel, sexual, and hormone-related problems [7] [8] [9] are treatment related, these patient-reported outcomes may also vary countywide. Despite this, little is known about regional differences in quality of survival. The National Prostate Cancer Audit reported some variation in outcomes for radical prostatectomy and radiotherapy patients by care providers within England and Wales [6] . However, these results were for localised disease only, while case-mix adjustment of results was not considered.
With many men living for long periods following their diagnosis, quality of survival has become increasingly important. Robust intelligence at regional and national levels may help identify improvements achievable through a wider application of practices adopted by the best performing areas. We have thus investigated variations in quality of survival between the four UK countries, and between Cancer Alliances within England.
Patients and methods
A cross-sectional postal survey of prostate cancer survivors was conducted as part of the Life After Prostate Cancer Diagnosis study [10] .
Data collection
Men diagnosed with prostate cancer in the previous 18-42 mo were identified from cancer registries in England, Wales, and NI, and from cancer registry-verified hospital activity data in Scotland. All health boards/trusts in Scotland, Wales, and NI and 111 out of 136 English NHS trusts participated. Overall, 82% of eligible prostate cancer survivors were posted a questionnaire between October 2015 and November 2016. Two reminders were sent and a Freephone helpline was available.
Men were requested to return completed surveys to an external provider (Picker Institute Europe). Stage at diagnosis, area-based quintile of socioeconomic deprivation (derived from the multiple deprivation measure for each nation [11] [12] [13] [14] ), and Cancer Alliance/Vanguard (CA) [15] of residence in England were added from cancer registration data.
Survey
The survey (Supplementary material) Absence of treatment along with reported active surveillance or watchful waiting was categorised as receiving monitoring only.
Health-related quality of life was evaluated using the EQ-5D-5L [17] , with responses coded as "no problems" and "with problems". The EuroQol
Visual Analogue Scale (EQ-VAS) [17] was used as a self-assessed health rating on a 0-100 scale, where higher scores represent better health.
Urinary, bowel, sexual, and vitality/hormonal functions were determined using the 26-item Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire [18] . Reported prevalence of specific problems was based upon the proportion of men reporting moderate/big problems (or equivalents such as poor/very poor) to individual questions. Summary scores for EPIC-26 domains were calculated by averaging standardised scores assigned to each question's responses in that domain. The possible range of scores is 0-100, with 100 corresponding to no problems.
Statistical analysis
Item completeness varied by region; thus, to reduce bias resulting from only including cases with complete data [19] , multiple imputation with chained equations [20] using all sociodemographic and clinical characteristics, and all EQ-5D-5L, EQ-VAS, and EPIC-26 questions and scores were utilised. Ten separate imputations were completed, with results combined using Rubin's rules [21] .
The EPIC-26 and EQ-VAS scores were modelled using log-linear Supplementary Fig. 1 ).
Almost two-thirds (64.0%) of respondents were diagnosed at stage I/II. East of England (68.9%), East Midlands (68.8%), and Wales (68.8%) had the highest proportion of stage I/II prostate cancers, while Scotland had the greatest proportion of stage IV disease (21.1%; Table 2 and Supplementary Fig. 1 ).
Three in 10 respondents (30.0%) reported having surgery. By country, this proportion was lowest in NI (15.6%), whilst there was considerable variation in surgery use within England (24.9% in East Midlands, 42.1% in Kent and Medway). Use of EBRT was highest in NI (49.2%) and lowest in Kent and Medway (25.8%). Use of ADT was highest in East Midlands (48.0%) and lowest in Kent and Medway (31.6%). Proportions of "monitoring only" ranged from 12.4% in Scotland to 20.7% in Kent and Medway (Table 2 and Supplementary Fig. 2 ).
3.3.
Unadjusted question responses Table 5 ).
3.4.
Case-mix-adjusted summary scores Table 3 ).
Within England
Within England, mean scores were 76.3 for self-assessed health, 81. Table 6 ). Table 1 for number of respondents by area). d Patients may receive more than one treatment type.
3.4.3.

Combined analysis
Including Wales, Scotland, and NI, along with the English CAs highlights similar regional variations. In general, men from Wales, Scotland, and NI report similar outcomes to, or worse outcomes than, those from CAs with below UK average outcome scores ( Fig. 2 and Supplementary Fig. 3 ).
Discussion
We report the largest, and to our knowledge first, evaluation of regional variations in prostate cancer patient-reported outcomes across the UK. Prostate cancer survivors living in England reported better quality of survival than those from Wales, Scotland, or NI. Within England, poorer than average self-assessed health was reported in South Yorkshire and North-East and Cumbria, while those from North-East and Cumbria, Peninsula, and West Midlands reported greater than average difficulties in one or more functional outcomes. Given that regional variations were independent of clinical case mix, treatment type, and sociodemographic characteristics, these inequalities require explanation.
Service implications
CAs were introduced in England in 2016 [15] , with a principal objective to reduce inequalities in cancer outcomes. The regional inequalities identified in this study reinforce the pressing importance for this remit to address not only survival, but also quality of that survival. A contributory cause of regional outcome variation may relate to regional differences in care provision. Detailed comparison of care pathways and packages of support, including availability and use of specific therapeutic modalities and support services, such as access to specialist nurses, could identify factors linked to enhanced quality of survival.
Regional differences may also relate to variation in general population health, as the morbidities reported are common among older men [22] . Overall and healthy life expectancy among men aged 65 yr are lower in Scotland, Wales, and NI than in England [23, 24] , with the North of England also having lower overall and healthy life expectancy compared with the South (with some exceptions such as Northumberland) [25] . Additionally, specific conditions (eg, cardiovascular disease) are more prevalent in the [ 5 _ T D $ D I F F ] North than in the South of England [26] , and in Scotland and NI than in England [27] , and vary by areabased socioeconomic status [28] . While these issues have broader service and public health implications, prostate cancer patients reporting functional problems as a result of conditions other than prostate cancer could still benefit from follow-up care.
Strengths and weaknesses
This study was population wide; thus, participation was not influenced by recruitment bias. However, 39.2% of patients did not respond to the survey, with regional variation in response rates and data completeness. In addition, a different participant identification process was utilised in Scotland, and not all the English NHS trusts managing prostate cancer participated. Cumulatively, this may have resulted in variation in outcome reporting as nonresponders may have different quality of life experiences than responders. However, given a response rate of over 60%, a sample size of approximately 35 800, and the utilisation of standardised/validated measures [29] , this study has ## CI = confidence interval; EPIC-26 = Expanded Prostate Cancer Index Composite; EQ-VAS = EuroQol Visual Analogue Scale; "" = higher than UK average (p < 0.001); " = higher than UK average (p < 0.05); # = lower than UK average (p < 0.05); ## = lower than UK average (p < 0.001). a Alive 18-42 mo after diagnosis. b This area-based comparison was conducted using log-linear regression, with results presented as adjusted predicted mean scores. Adjustments were made for age, socioeconomic deprivation, employment status, marital status, ethnicity, comorbidities, history of mental health problems, body mass index, method of presentation, stage at diagnosis, and treatment types received. These scores differ from values determined directly from raw data. Higher mean scores represent better health or fewer difficulties in that domain. c n = 35 823 (see Table 1 for number of respondents by area).
[ ( F i g . _ 1 ) T D $ F I G ] Table 1 for the number of respondents by area). This area-based comparison was conducted using log-linear regression, with results presented as adjusted predicted mean scores. Adjustments were made for age, socioeconomic deprivation, employment status, marital status, ethnicity, comorbidities, history of mental health problems, body mass index, method of presentation, stage at diagnosis, and treatment types received. These scores differ from values determined directly from raw data. Higher mean scores represent better health or fewer difficulties in that domain. See Supplementary Fig. 4 18-42 mo after diagnosis.
sufficient statistical power to allow meaningful interpretation and intercountry benchmarking. The case-mix adjustment applied indicates that differences are unlikely to be related to treatment type, comorbidity, or socioeconomic status. However, this should only be interpreted in a broad sense, as adjustments were based on self-reported treatment with no adjustment possible for treatment intensity (eg, frequency, radiation fraction, and ADT type) or when patients finished treatment. The latter may be of particular relevance, as while the 18-42 mo time frame was chosen because it represents the period when initial treatment is complete and quality of life has begun to stabilise [9, 10] , a wide range of possible patient pathways and timelines exists. In addition to the above, information on quality of life before diagnosis or equivalent baseline population data was not available. Adjustments for background morbidity levels were thus limited to accounting for age, number of comorbidities, and BMI, which reduces the ability to establish causal links. Finally, the use of area-based socioeconomic deprivation measures and employment status at a single time point may not fully reflect individual-level socioeconomic status.
Whilst statistically significant differences were identified, there is no consensus as to what magnitude of difference is clinically meaningful for the EQ-VAS and EPIC-26 scores when applied across populations. For individuallevel comparisons, the work of Skolarus et al. [30] for EPIC-26 and Pickard et al. [31] for EQ-VAS suggests that only Table 1 for the number of respondents by area). This area-based comparison was conducted using log-linear regression, with results presented as adjusted predicted mean scores. Adjustments were made for age, socioeconomic deprivation, employment status, marital status, ethnicity, comorbidities, history of mental health problems, body mass index, method of presentation, stage at diagnosis, and treatment types received. These scores differ from values determined directly from raw data. Higher mean scores represent better health or fewer difficulties in that domain. Funnel plots of these data are available in Supplementary Fig. 3 . EPIC-26 = Expanded Prostate Cancer Index Composite; EQ-VAS = EuroQol Visual Analogue Scale.
a Alive 18-42 mo after diagnosis. The figure contains OS data (GB) and LPS Intellectual Property (NI) Crown copyright and database right 2018.
differences between the worst and best performing areas for bowel and vitality/hormonal function may qualify as being clinically relevant. In addition, it is important to note that conclusions about variations at a regional level may not necessarily reflect the experience of every patient.
Importance of patient-reported outcomes
There is a need to ensure that patient-reported outcomes are central and core components of cancer outcomes research, in order to increase the probability that conclusions are appropriately "patient centred". There are few examples of their use in national surveys that are comprehensive and adequately powered enough to provide robust data on regional variations. This study has tackled this issue in a common and complex cancer, and has demonstrated that this is feasible and necessary, with the generation of useful intelligence regarding variations between and within countries. Identification of such variations can lead to enhanced care provision though identification of differences in patient pathways in the best and worst performing areas.
Conclusions
Quality of survival among prostate cancer survivors varies across the UK, with poorer outcomes reported by men from Scotland, Wales, and NI than by men from England
Regional variation was also demonstrated within England. These findings highlight the need for further investigation to identify components of care pathways that predispose to good or poor outcomes, particularly with regard to bowel problems and vitality, where clinically relevant differences were reported. Action is required to ensure that outcomes are monitored and, where possible, improved so that the increasing number of men living with and beyond a diagnosis of prostate cancer [ 8 _ T D $ D I F F ] are offered the best chance of achieving optimal quality of survival.
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